AbbVie has announced its financial results for the fourth quarter and full-year periods of 2017, during which the company was able to achieve robust growth.
The firm generated full-year net revenues of $28.22 billion (GBP 20.05 billion), which represented a year-on-year increase of 10.1 percent on an operational basis. For the fourth quarter, AbbVie's revenues reached $7.74 billion, up by 12.1 percent in operational terms.
“AbbVie has reported strong year-on-year financial growth during the fourth quarter and full-year periods of 2017.“
During the year, the company saw double-digit percentage sales increases for key products such as Humira and Imbruvica, while reporting positive results from clinical trials for therapies such as upadacitinib and risankizumab.
AbbVie has raised its previously announced adjusted earnings per share guidance range for 2018 from $6.37 to $6.57 to a new range of $7.33 to $7.43, reflecting the impact of US tax reform and the company's recent improved operating performance.
Richard Gonzalez, chairman and chief executive officer at AbbVie, said: "This is an exciting time for AbbVie - we are poised to launch a number of differentiated products over the next 12 to 18 months that will fuel significant growth in the coming years."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical